Key Takeaways
- 68% of CSOs surveyed say AI has already changed at least one core R&D process in their organisation, up from 31% the prior year, according to Life Sciences Weekly Research polling of 500 executives.
- Organisations that integrated AI into target identification before 2025 report a median 22% reduction in early-stage cycle times, compared with 6% for late adopters.
- Portfolio culling is accelerating: 41% of respondents terminated at least two programmes in the past 12 months on the basis of AI-generated efficacy modelling, a practice almost unheard of three years ago.
- The talent gap is the single biggest constraint cited by CSOs: 57% say their organisations lack the computational biology expertise needed to fully operationalise AI-driven discovery pipelines.
Twelve months ago, AI in drug discovery was a pilot project. Today, it is a board-level pressure point. The Life Sciences Weekly Research survey of 500 senior executives, conducted in March 2026, reveals an industry in genuine strategic transition: 68% of chief scientific officers report that AI has already changed at least one core R&D process, up from 31% in the equivalent 2025 poll. That is not incremental adoption. That is a structural shift arriving faster than most governance frameworks, talent pipelines, or capital allocation models were built to handle. The CSOs who are navigating it well share three characteristics: they redefined the CSO remit before the board forced the conversation, they invested in data infrastructure ahead of model deployment, and they are ruthlessly portfolio-focused.
Discovery Has a New First Principle: Let the Model Decide
For decades, target identification in drug discovery was a combination of literature review, biological intuition, and institutional knowledge. AI is dismantling that model with speed that surprises even advocates. In the Life Sciences Weekly survey, organisations that integrated AI into target identification before 2025 report a median 22% reduction in early-stage cycle times. Late adopters, those embedding AI in 2025 or after, report only a 6% improvement. The gap is widening, not closing. The CSOs who made the early commitment describe a compounding advantage: better-quality targets mean fewer failures downstream, which frees capital for the next generation of programmes.
But speed is only part of the story. The more significant shift is epistemic. The chief scientific officer of a top-20 global pharmaceutical company described a moment last year when an AI platform flagged a target the scientific team had explicitly ruled out six months earlier. The model was right. That experience, repeated across several organisations in our survey, is prompting a fundamental reappraisal of how scientific judgement and computational inference are weighted in early-stage decisions.
Portfolio Culling Is Now a Competitive Weapon
The most striking data point in the survey is not about discovery. It is about termination. Forty-one per cent of respondents say they killed at least two programmes in the past 12 months on the basis of AI-generated efficacy modelling. Three years ago, that figure was statistically negligible. The implication is significant: CSOs are using AI not just to advance programmes faster, but to exit failing ones earlier, before Phase II spend compounds a bad bet.
The financial logic is straightforward. A programme terminated at the end of lead optimisation costs a fraction of one killed after a failed Phase II trial, where the bill typically exceeds $80 million. The CSOs driving the most aggressive culling strategies tend to sit inside organisations where the board has explicitly endorsed AI-informed go/no-go gates, giving scientific leadership the political cover to act on model outputs rather than defend legacy investments.
"We stopped thinking of AI as a tool that supports our decisions. We now treat it as a decision-maker that requires a human override justification. That inversion changed everything about how we build the portfolio."
Chief Scientific Officer at a large European pharmaceutical group (survey respondent)
The Talent Bottleneck Is the Real Strategic Risk
Fifty-seven per cent of CSOs identify a shortage of computational biology expertise as the primary constraint on AI adoption, ahead of data quality issues (44%) and regulatory uncertainty (38%). The talent problem is particularly acute at the intersection of machine learning engineering and biological domain knowledge: people who can build and interrogate models and understand what the outputs mean in a therapeutic context. Universities are not producing them at the required rate.
The organisations managing this constraint most effectively are not simply recruiting harder. They are restructuring scientific teams to pair computational specialists with traditional biologists in dedicated discovery units, and they are acquiring small AI-native biotechs specifically for the talent rather than the pipeline. The CSO of a mid-sized oncology-focused biotech estimated that two-thirds of the organisation's AI capability arrived through three acqui-hires completed between 2024 and 2025, each valued at under $50 million.
- Infrastructure before models: CSOs report the highest AI ROI where clean, standardised data repositories were established at least 18 months before model deployment began, making data governance the true first investment.
- Governance before scale: Organisations with a formal AI review committee, including scientific, legal, and regulatory representation, report significantly higher board confidence in AI-informed portfolio decisions and fewer costly reversals.
- Talent before tools: Acquiring or developing hybrid computational-biological talent before selecting AI platforms produces better outcomes than deploying platforms and then recruiting to support them, according to 63% of high-adoption respondents.
The 2026 survey paints a picture of an industry at an inflection point where the gap between AI leaders and AI followers is compounding with each annual cycle. CSOs who embedded AI into core discovery and portfolio processes before 2025 now hold structural advantages in cycle time, capital efficiency, and scientific throughput that are difficult to close quickly. For organisations still treating AI as a supplementary capability rather than a core strategic one, the window to close that gap is narrowing. The question for every chief scientific officer entering the second half of 2026 is not whether to integrate AI into R&D strategy. It is whether their governance, talent, and data infrastructure are ready to make that integration count before the competition makes the choice irrelevant.
